Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy of Patients with CLL with Mutated IGHV and Without Deletion 17p
CLL, Chemotherapy, Ibrutinib, Frontline Treatment, Mutated IGHV
Publication date: Available online 6 December 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Rafiye Ciftciler, Haluk Demiroglu, Yahya Buyukasık, Elifcan Aladag, Salih Aksu, Ibrahim C. Haznedaroglu, Nilgun Sayınalp, Osman Ozcebe, Umit Yavuz Malkan, Hakan GokerAbstractBackground and AimThe refractory acute myeloid leukemia (AML) includes patients who fail standard induction chemotherapy, relapse within 6 months after first complete remission and relapse twice or more. The outcome of these patients is usually very poor with only a small proportion could be rescued by allogenic hematopoietic stem cell transplan...
The refractory acute myeloid leukemia (AML) includes patients who fail standard induction chemotherapy, relapse within 6 months after first complete remission and relapse twice or more. The outcome of these patients is usually very poor with only a small proportion could be rescued by allogenic hematopoietic stem cell transplantation (alloHSCT). The aim of this study is to evaluate the efficacy and feasibility of alloHSCT in patients with refractory AML.
ConclusionResults of real-life studies differ from those found by prospective trials. Accordingly, early actions and supportive care are still needed, aiming to decrease toxicity, especially in developing countries.
ConclusionsFulminant febrile, hypotensive reactions can be seen following ABVD treatment for cHL. In the present series symptoms resolved within 24 hours with the use of intravenous corticosteroids and intensive supportive care.
ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) is a widely used frontline regimen for the treatment of early and advanced stage classical Hodgkin ’s lymphoma (cHL). A fulminant syndrome characterized by pyrexia and shock was observed in early trials of bleomycin, occurring more frequently in patients with lymphoma. In the past three decades, only one case of a similar fulminant reaction following ABVD has been reported and thus there is lim ited literature regarding the risk factors, clinical course, and management for this life threatening syndrome.
ConclusionThis review provides estimates for response and survival to aid in decision making when considering ASCT for patients with PCNSL.
ConclusionsProphylactic antiviral therapy is not a cost-effective strategy for the management of lymphoma patients with past HBV infection, especially those positive for anti-HBs.
While primary central nervous lymphoma (PCNSL) is sensitive to methotrexate chemotherapy, more than half of patients will relapse within five years. Autologous stem-cell transplant (ASCT) is increasingly used as consolidative treatment. This systematic review and meta-analysis provides estimates for response and survival after ASCT and suggests improved rates compared to the historical data.
Conclusion: While providing potential clinical benefit, CAR T cell therapy utilizes resources across the therapeutic spectrum, and increasing use of this therapeutic modality can create challenges in institutional resource capacity. Identifying these resources will allow for better care delivery and allocation of funds. Further refinement of CAR T cell products and improvements in CAR T cell-related toxicity management may permit safer delivery of this therapy and reduce costs per patient. Additional analysis of resource utilization among patients treated with commercial CAR T cell products, as well as comparison with alte...
Conclusion: Liver injury associated with the autologous hematopoietic stem cell transplant, represented mainly by DILI and SOS, had a high incidence (18.9%) among the subjects in the study and was associated with an elevated mortality rate. Drug induced liver injury has been underestimated and deserves further studies.DisclosuresNo relevant conflicts of interest to declare.